Chemokine Analogs: Unlocking the Power of the Immune System

We are engineering novel chemokine analogues which have the potential to offer superior potency and safety profiles versus traditional drug classes of small molecules and antibodies

Leading to the development of promising new therapies for Cancer and other serious diseases

5P12Rantest Adjusted
Our lead drug candidate – OB-002 – has demonstrated best-in-class potency as well as an excellent safety profile in pre-clinical testing and is now in a phase 1 clinical trial

A Growing Pipeline

We are accelerating the identification and lead optimization of chemokine analogues and other small proteins.   Current efforts are focused on the identification of novel chemokine analogues for the treatment of other serious diseases.

Recognized
Leadership

Dr. Oliver Hartley
“I am delighted with how Orion has accelerated the development of OB-002 and I am looking forward to introducing new chemokine analogs into the pipeline”
Dr. Ian McGowan MD, Phd, FRCP
“The development of novel safe and efficacious immunotherapeutic products is the next frontier in cancer therapy – I am delighted that Orion Biotechnology is part of this adventure”
Previous
Next

Global Headquarters

343 Preston Street

11th floor,

Ottawa, On K1S 1N4

CANADA

+1 343.291.1032

Switzerland

Campus Biotech

Innovation Park

Avenue de Sécheron 15

1202 Genève

SWITZERLAND

Poland

Orion Biotechnology

Life Science Park

UI Bobrzyńskiego 14

30-348 Krakôw

POLAND

CONTACT:  info@orionbiotechnology.com

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

+1 343.291.1032

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

+1 343.291.1032